{"id":49661,"date":"2024-12-18T18:47:45","date_gmt":"2024-12-18T18:47:45","guid":{"rendered":"https:\/\/www.fomatmedical.com\/?p=49661"},"modified":"2024-12-18T18:47:45","modified_gmt":"2024-12-18T18:47:45","slug":"what-hypertriglyceridemia-clinical-trials-are-teaching-us-about-triglyceride-lowering-medications","status":"publish","type":"post","link":"https:\/\/fomatmedical.com\/es\/blogs-updates\/what-hypertriglyceridemia-clinical-trials-are-teaching-us-about-triglyceride-lowering-medications\/","title":{"rendered":"Lo que los ensayos cl\u00ednicos sobre hipertrigliceridemia nos ense\u00f1an sobre los medicamentos para reducir los triglic\u00e9ridos"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Hypertriglyceridemia, or high triglyceride levels, can pose serious health risks, but thanks to ongoing clinical trials, we’re learning more than ever about how to manage this condition. These studies are helping us better understand the role triglycerides play in heart and metabolic health while driving the development of new and innovative treatments. From well-known options like omega-3 fatty acids to cutting-edge therapies like gene editing, there\u2019s a lot of progress being made. Let\u2019s dive into the basics of understanding triglycerides and hypertriglyceridemia, what these trials teach us, and explore how they\u2019re shaping the future of triglyceride management.\u00a0<\/span><\/p>

What are Triglycerides?<\/span><\/h2>

Triglycerides are a type of fat in the blood. They are made from the food we eat, particularly fats and carbs, and are used as energy. Excess calories are converted to triglycerides and stored in fat cells for later use. Unlike cholesterol, which plays a structural role in cell membranes and is a precursor to certain hormones, triglycerides are just energy.<\/span><\/p>

How Does Hypertriglyceridemia Develop?<\/span><\/h2>

Hypertriglyceridemia occurs when triglyceride levels are above normal, typically above 150 mg\/dL. This can be due to a combination of genetic predisposition and secondary factors such as obesity, a high-carb diet, excessive alcohol consumption, and a sedentary lifestyle. Certain medical conditions like diabetes and hypothyroidism and medications like steroids and beta-blockers can also contribute.<\/span><\/p>

Why is it Dangerous?<\/span><\/h2>

High triglycerides are linked to serious health risks, including cardiovascular disease (CVD), such as atherosclerosis, where arteries become clogged and lead to heart attacks and strokes. Severe cases can trigger acute pancreatitis, a life-threatening condition. Hypertriglyceridemia often coexists with other metabolic disorders like insulin resistance and forms a vicious cycle that amplifies the health risks.<\/span><\/p>

Pharmacological Treatments<\/span><\/h2>

Managing hypertriglyceridemia often requires a combination of therapies based on the patient\u2019s risk profile and triglyceride levels. Below, we will look at the pharmacological options, their mechanism of action, efficacy and clinical considerations.<\/span><\/p>

Niacin<\/span><\/h3>

How it works:<\/span><\/i><\/h4>

Niacin (vitamin B3) was the first drug approved to treat hyperlipidemia and has been on the market for this condition since around 1955. Niacin controls hypertriglyceridemia by inhibiting the liver\u2019s ability to produce VLDL (very low-density lipoproteins), a precursor to LDL (low-density lipoprotein or \u201cbad\u201d cholesterol). It also increases HDL (high-density lipoprotein or \u201cgood\u201d cholesterol).<\/span><\/p>

Efficacy:<\/span><\/i><\/h4>

Clinical trials for hypertriglyceridemia have shown that niacin can reduce triglycerides by around 20%, depending on the dose\u2014with side effects including flushing, itching and liver toxicity.<\/span><\/p>

A study found that extended-release niacin reduced LDL cholesterol (LDL-C) more in women than men at all doses and triglycerides (TG) at 1,500 mg. This may be due to women\u2019s lower body mass and higher circulating niacin levels. Effects on HDL cholesterol (HDL-C) and lipoprotein(a) [Lp(a)] were similar for both sexes, and niacin\u2019s lipid-lowering effects were dose-dependent. However, its use has declined due to a lack of evidence linking it to reducing cardiovascular events.<\/span><\/p>

Clinical Considerations:<\/span><\/i><\/h4>